Cogent Biosciences (COGT) Shares Outstanding (Diluted Average) (2021 - 2026)
Cogent Biosciences (COGT) recorded quarterly Shares Outstanding (Diluted Average) of $162.2 million in Q1 2026, up 25.83% quarter-over-quarter from $128.9 million in Q4 2025, and up 43.15% on a YoY basis from $113.3 million in Q1 2025.
Cogent Biosciences (COGT) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Cogent Biosciences' Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $162.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 43.15% year-over-year to $162.2 million; the TTM figure through Mar 2026 stood at $162.2 million (up 43.15% YoY), while the FY2025 annual figure was $128.9 million, up 24.11% from the prior year.
- Shares Outstanding (Diluted Average) was $162.2 million for Q1 2026 at Cogent Biosciences, up from $128.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $162.2 million in Q1 2026 to a low of $77968.0 in Q3 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $89.2 million across 5 years, with a median of $97.0 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) plunged 99.86% in 2023, then surged 141195.89% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $58.7 million in 2022, then soared by 35.61% to $79.7 million in 2023, then soared by 30.38% to $103.9 million in 2024, then advanced by 24.11% to $128.9 million in 2025, then climbed by 25.83% to $162.2 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $162.2 million (Q1 2026), $128.9 million (Q4 2025), and $137.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 92.44 Mn |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - | 162.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.19 Mn |
| Dec 31, 2025 | 128.90 Mn |
| Sep 30, 2025 | 137.55 Mn |
| Jun 30, 2025 | 114.47 Mn |
| Mar 31, 2025 | 113.31 Mn |
| Dec 31, 2024 | 103.86 Mn |
| Sep 30, 2024 | 110.17 Mn |
| Jun 30, 2024 | 99.24 Mn |
| Mar 31, 2024 | 94.80 Mn |
| Dec 31, 2023 | 79.66 Mn |
| Sep 30, 2023 | 77,968.00 |
| Jun 30, 2023 | 74.75 Mn |
| Dec 31, 2022 | 58.74 Mn |
| Sep 30, 2022 | 54.78 Mn |
| Jun 30, 2022 | 49.39 Mn |
| Mar 31, 2022 | 45.11 Mn |
| Dec 31, 2021 | 38.73 Mn |
| Sep 30, 2021 | 39.85 Mn |
| Jun 30, 2021 | 38.44 Mn |